Events

Norwegian Oncology Lunch Seminar

CEO of Oncoinvent, Jan A. Alfheim, will be presenting the company at ABGSC Norwegian Oncology Seminar November 23 at 12:50

Organiser: ABG Sundal Collier
Venue:

ABG Sundal Collier
Ruseløkkveien 26, 8th floor.
Oslo


Date: November 23, 2022 12:50 pm

Dosimetry data from the Phase I expansion cohort of Radspherin® in colorectal cancer patients to be presented at the 2022 EANM Annual Meeting

The aim of this study was to estimate the absorbed doses to normal tissues for patients injected intraperitoneally with a suspension of radium-224 adsorbed in calcium carbonate microparticles (224Ra-CaCO3-MP) for treating peritoneal carcinomatosis originating from colorectal cancer.

Organiser: EANM 2022
Venue:

CCIB – Centre de Convencions Internacional
de Barcelona / Barcelona International
Convention Centre
Hall 111

e-Poster Presentation Session 11 – Dosimetry

Committee: Dosimetry – Novel Tracers and Computer-Based Modelling


Date: October 18, 2022 3:00 pm
Program

Oncoinvent to present at the LSX Nordic biotech congress

CEO, Jan A. Alfheim, will be speaking at the LSX Nordic Biotech Congress and host 1-on-1 meetings with investors on 6-7 September, 2022

Organiser: LSXNordic
Venue:

Bella Sky, Center Blvd. 5, 2300 Copenhagen, Denmark


Date: September 6, 2022 12:00 am
Program

Invitation to a Presentation of the 1st Quarter 2022 Results

Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor.

To attend, please register with kvam@oncoinvent.com.


Oncoinvent ønsker med dette å invitere til presentasjon av resultater for 1. kvartal 2022. Presentasjonen vil holdes onsdag 1. juni 2022, kl. 08:30 i selskapets lokaler i Gullhaugsveien 7, Oslo, 3. etasje.

Vi ber om at deltakere registrerer seg ved å sende en e-post til kvam@oncoinvent.com.

Organiser: Oncoinvent
Venue:

Gullhaugsveien 7, Oslo, 3rd Floor.


Date: June 1, 2022 8:30 am

DNB’s Small & Medium Enterprises Conference 2022

CEO, Jan A. Alfheim, will present Oncoinvent at the DNB Small & Medium Enterprises Conference and host 1-on-1 meetings with investors on April 7, 2022

Organiser: DNB
Venue:

Dronning Eufemias gate 30, Oslo, Norway


Date: April 7, 2022 9:50 am
Program

Oncoinvent to participate in the 2022 Credit Suisse London Healthcare Conference

Organiser: Credit Suisse
Venue:

Company management will participate in 1×1 meetings


Date: March 2, 2022 12:00 am
Program

Oncoinvent to participate in the B. Riley Radiation-Oncology Investor Day

Organiser: B. Riley Financial, Inc.
Venue:

Oncoinvent will participate in fireside chat in the B. Riley Radiation Oncology Investor Day


Date: February 22, 2022 4:30 pm
Program

Oncoinvent to present at DNB’s 12th Nordic Healthcare Conference

Organiser: DNB
Venue:

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announces that its CEO, Jan A. Alfheim will present the company at a live webcast at DNB’s 12th Nordic Healthcare Conference on 16 December 2021. The presentation will take place from 10:45-11:05 CET.


Date: December 16, 2021 10:45 am
Program

Invitation to a Presentation of the 3 Quarter 2021 Results

Oncoinvent would like to extend an invitation to a presentation of the Q3 2021 results. The presentation will be held virtually via Teams at 09:00 on Friday 12. November 2021.

We request that participants register with kvam@oncoinvent.com for logon details.

Organiser: Oncoinvent
Venue:

Virtual on Teams


Date: November 12, 2021 9:00 am

34th Annual Congress of the European Association of Nuclear Medicine

Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine

Organiser: European Association of Nuclear Medicine
Venue:

Virtual


Date: October 20, 2021 12:00 am
Program

Invitation to a Presentation of the 2 Quarter 2021 Results

Oncoinvent would like to extend an invitation to a presentation of the Q2 2021 results. The presentation will be held virtually via Teams at 09:00 on Thursday 9. September 2021.

We request that participants register with kvam@oncoinvent.com for logon details.

Organiser: Oncoinvent AS
Venue:

Virtual


Date: September 9, 2021 9:00 am

Stern IR: Virtual meetings during J.P. Morgan 2021 Health Conference January 11-14, 2021

Virtual Event organized by Stern IR at time of J.P. Morgan 2021 Health Conference: January 11-14, 2021

Oncoinvent CEO, Jan A. Alfheim will present the company at Stern IR’s  event that is scheduled to occur during the virtual J.P. Morgan Healthcare Conference . The presentation is awailable at https://wsw.com/webcast/sternir/oncoi/2294600.

 

Organiser: Stern IR
Venue:

Virtual


Date: January 11, 2021 1:00 pm
Program

Invitation to a Presentation of the 3. Quarter 2020 Results

Oncoinvent would like to extend an invitation to a presentation of the Q3 2020 results. The presentation will be held virtually at 10:00 on Friday 23. October 2020. We request that participants register with kvam@oncoinvent.com for logon details.

The quarterly report will be made available on www.oncoinvent.com on the 23. October 2020.

Organiser: Oncoinvent AS
Venue:

Virtual


Date: October 23, 2020 10:00 am

Oncoinvent to present a e-poster at the European Association of Nuclear Medicine (EANM) Congress

Oncoinvent will present the e-poster “Size-controlled 224Ra-labelled calcium carbonate microparticles against peritoneal carcinomatosis” at the virtual 33rd annual European Association of Nuclear Medicine (EANM) Congress. The abstract (no. EP-290) can be downloaded here.

Organiser: European Association of Nuclear Medicine
Venue:

Virtual


Date: October 22, 2020 12:00 pm
Program

Oncoinvent to present at Nordic American Life Science Conference 2020

Oncoinvent CEO, Jan A. Alfheim will present the company at the virtual Nordic American Life Science Conference.

Organiser: Nordic American Lifscience
Venue:

Virtual


Date: October 22, 2020 10:10 am
Program

Oncoinvent presented at Hadean Ventures Annual Event 2020

Oncoinvent CEO, Jan A. Alfheim presented the company at the virtual Hadean Ventures Annual Event 2020. The presentation is available here (https://www.youtube.com/watch?v=f_cJUHC4vSg&feature=emb_logo).

 

 

Organiser: Hadean Ventures
Venue:

Virtual


Date: October 21, 2020 12:00 pm

Oncoinvent to present at DNB Nordic Healthcare Conference 2019

Oncoinvent CEO, Jan A. Alfheim will present the company at the DnB Nordic Healthcare Conference 2019 at the venture session for scaleups.

Organiser: DnB
Venue:

Audioturium 1

Dronning Eufemias gate 30,

Oslo, Norway


Date: December 12, 2019 3:35 pm
Program

Oncoinvent to present at Nordic American Life Science Conference 2019

Oncoinvent CEO, Jan A. Alfheim will present the company at the Nordic American Life Science Conference in New York, USA 

Organiser: Nasdaq, DNB, Business Sweden
Venue:

Well Said, Convene, 151 West 42nd Street, New York, NY 10036


Date: December 5, 2019 2:30 pm
Program

Invitation to a Presentation of the Third Quarter 2019 Results

Oncoinvent would like to extend an invitation to a presentation of the Q3 2019 results. The presentation will be held at 14:00 on Thursday 31. October 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.

To attend, please register with 

kvam@oncoinvent.com

The quarterly report will be made available on www.oncoinvent.com on the 31. October 2019

Organiser: Oncoinvent AS
Venue:

Gullhaugsveien 7, Oslo


Date: October 31, 2019 2:00 pm
Program

Outsourcing in Clinical Trials and Clinical Trial Supply Nordics

Head of Clinical Operations at Oncoinvent, Helen Johansen Blanco will be presenting at the conference “Outsourcing in Clinical Trials and Clinical Trial Supply Nordics”.

Organiser: Arena Event International
Venue:

Scandic Copenhagen, Denmark

 


Date: October 22, 2019 3:00 pm
Program

European Association of Nuclear Medicine (EANM) 2019

CSO Tina Bønsdorff, presented the ePoster «Feasibility of Ra-224 SPECT CT imaging in a therapeutic setting – a phantom study» developed by Stokke (PhD, Assoc. Prof) and Mikalsen (PhD) at Oslo University Hospital, Oslo, NORWAY, at the European Association of Nuclear Medicine (EANM) annual conference held in Barcelona.

Organiser: European Association of Nuclear Medicine (EANM)
Venue:

CCIB – Centre de Convencions Internacional de Barcelona,
Placa de Willy Brandt, 11-14
08019 Barcelona, Spain


Date: October 16, 2019 12:00 am
Program

Presentation of the Second Quarter 2019 Results

Oncoinvent would like to extend an invitation to a presentation of the Q2 2019 results. The presentation will be held at 15:00 on Thursday 29. August 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.

Going forward quarterly result presentations will be held on a regular basis.

To attend, please register with
kvam@oncoinvent.com

The quarterly report will be made available on www.oncoinvent.com on the 29. August 2019

Organiser: Oncoinvent AS
Venue:

Gullhaugsveien 7, Oslo


Date: August 29, 2019 3:00 pm
Program

Oncoinvent to present poster at the SNMMI 2019 Annual Meeting

Oncoinvent researcher Elisa Napoli will present the poster “A primary activity standard for the alpha-emitting radionuclide Ra-224” at the SNMMI 2019 Annual Meeting.

Organiser: Society of Nuclear Medicine & Molecular Imaging
Venue:

SNMMI 2019 Annual Meeting, Anaheim, CA


Date: June 25, 2019 12:00 am
Program

Oncoinvent to present at ABGSC Norwegian Biotech Oncology Seminar

Jan A. Alfheim, CEO of Oncoinvent will give a short status presentation about the company at the ABG Sundal Collier’s Norwegian Biotech Oncology Seminar

Organiser: ABGSC
Venue:

ABG Sundal Collier, Munkedamsveien 45E, 7th floor, Oslo, Norway


Date: June 11, 2019 11:00 am
Program

Oncoinvent to present at International Cancer Cluster Showcase

Oncoinvent CEO Jan A. Alfheim will be presenting the company during the International Cancer Cluster Showcase at the BIO International Convention 2019.

Organiser: BIO International
Venue:

BIO International, Pennsylvania Convention Center, Room : 204B, level 200, 1101 Arch St, Philadelphia, PA 10107, USA


Date: June 3, 2019 12:00 am
Program

Oncoinvent to present at the Venture Session of DNB’s 8th Annual Nordic Healthcare Conference 2017

Oncoinvent CEO Jan A. Alfheim will be presenting at 10:25 during the morning Venture Session on Thursday the 14th of December

Organiser: DnB
Venue:

DNB Bank, Dronning Eufemias Gate 30, Bjørvika, 0191 Oslo, Norway


Date: December 14, 2017 8:30 am
Program

Oncoinvent to present preclinical efficacy data in a poster session at the 20th Biennial Meeting of the European Society of Gynaecological Oncology (ESGO 2017)

The poster ‘Preclinical Evaluation of a Novel Alpha-Particle Emitting Therapeutic Agent for Intraperitoneal Therapy of Peritoneal Metastases’ by Oncoinvent scientists Tina B. Bønsdorff, Sara Westrøm, Øyvind S. Bruland and Roy H. Larsen will be presented at the congress.

Organiser: ESGO
Venue:

Austria Center Vienna, Bruno Kreisky Platz 1, Vienna, 1210 Austria


Date: November 4, 2017 9:30 am
Program

Oncoinvent to present at the 30th Annual Congress of the European Association of Nuclear Medicine – EANM

Researchers Sara Westrøm and Elisa Napoli will each be presenting findings of their research during the morning session on Sunday the 22nd of October

Organiser: EANM
Venue:

Austria Center Vienna, Bruno Kreisky Platz 1,Vienna, 1210 Austria


Date: October 21, 2017 8:00 am

Oncoinvent Update – Radforsk Podcast

Oncoinvent CEO Jan A. Alfheim speaks with Radforsk’s Jónas Einarsson and Elisabeth Kirkeng Andersen

Organiser: RADFORSK
Venue:

Ullernchausséen 64 – 66, 0379 Oslo, Norway


Date: October 18, 2017 12:00 am
Program

Oncoinvent to present at Partnership4Life Symposium

CEO Jan A. Alfheim will give a company presentation at the upcoming Partnership4Life symposium on February 15.

Organiser: The Life Science Cluster
Venue:

Forskningsparken, Gaustadaléen 21 Oslo, Norge


Date: February 15, 2017 12:00 pm
Program

DNB Health Care Conference

Organiser:
Venue:

DNB BANK, Dronning Eufemiasgate 30, Bjørvika, NO- 0191 Oslo


Date: December 15, 2016 8:30 am
Program

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.